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thromboembolism (VTE) who had a signiﬁcant bleeding risk.Background The effectiveness of inferior vena cava ﬁlter use among patients with acute symptomatic VTE and known signiﬁcant
bleeding risk remains unclear.Methods In this prospective cohort study of patients with acute VTE identiﬁed from the RIETE (Computerized Registry of
Patients With Venous Thromboembolism), we assessed the association between inferior vena cava ﬁlter insertion
for known signiﬁcant bleeding risk and the outcomes of all-cause mortality, pulmonary embolism (PE)-related
mortality, and VTE rates through 30 days after the initiation of VTE treatment. Propensity score matching was used
to adjust for the likelihood of receiving a ﬁlter.Results Of the 40,142 eligible patients who had acute symptomatic VTE, 371 underwent ﬁlter placement because
of known signiﬁcant bleeding risk. A total of 344 patients treated with a ﬁlter were matched with 344
patients treated without a ﬁlter. Propensity score–matched pairs showed a nonsigniﬁcant trend toward lower
risk of all-cause death for ﬁlter insertion compared with no insertion (6.6% vs. 10.2%; p ¼ 0.12). The risk-
adjusted PE-related mortality rate was lower for ﬁlter insertion than no insertion (1.7% vs. 4.9%; p ¼ 0.03).
Risk-adjusted recurrent VTE rates were higher for ﬁlter insertion than for no insertion (6.1% vs. 0.6%;
p < 0.001).Conclusions In patients presenting with VTE and with a signiﬁcant bleeding risk, inferior vena cava ﬁlter insertion compared
with anticoagulant therapy was associated with a lower risk of PE-related death and a higher risk of recurrent
VTE. However, study design limitations do not imply a causal relationship between ﬁlter insertion and outcome.
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DVT = deep vein thrombosis
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LMWH = low-molecular-
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PE = pulmonary embolism
UFH = unfractionated
heparin
VTE = venous
thromboembolism
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1676Despite the advances in the
diagnosis and management of
venous thromboembolism (VTE),
deep vein thrombosis (DVT) and
pulmonary embolism (PE) remain
major causes of morbidity and
mortality (1). Conventional treat-
ment for VTE consists of the
use of parenteral agents (i.e.,
unfractionated heparin [UFH],
low-molecular-weight heparin
[LMWH], fondaparinux) as a
“bridge” for oral anticoagulation
therapy (2). Guidelines do not
recommend insertion of a ﬁlter in
the inferior vena cava (IVC) as
the primary treatment of VTE.
A large population-based retro-spective analysis, which assessed for recurrent VTE in pati-
ents treated with an IVC ﬁlter for acute VTE, found that
the use of a ﬁlter was associated with a higher incidence
of rehospitalization for venous thrombosis among patients
who initially manifested PE (3). Stein et al. (4) showed that
the all-cause in-hospital case fatality rate was lower among
patients with unstable PE who received thrombolytic therapy
and had a vena cava ﬁlter. In the only clinical trial that eval-
uated the efﬁcacy of vena cava ﬁlters (in addition to standard
anticoagulant therapy), this treatment reduced the risk of
PE but increased that of DVT and had no effect on survival
(5). An 8-year follow-up of the patients enrolled in the
PREPIC (Prevention of Recurrent Pulmonary Embolism by
Vena Cava Interruption) trial showed similar results (6).page 1684In the absence of randomized clinical trials that demon-
strate a mortality beneﬁt of IVC ﬁlter treatment of VTE,
the American College of Chest Physicians guidelines mainly
limit their recommendation for IVC ﬁlter insertion to
patients with acute symptomatic VTE and a contraindication
to anticoagulation (grade 1B) (2). Unfortunately, studies have
not clearly determined which patients with VTE would
beneﬁt from vena cava ﬁlter therapy.
Given the lack of data supporting a survival beneﬁt of
IVC ﬁlter therapy in patients with acute VTE, we conducted
the present study using data collected for an international
multicenter (Online Appendix) (7,8). The study assessed
the association between the insertion of an IVC ﬁlter and
mortality and other outcomes during the ﬁrst month after
treatment for acute symptomatic VTE in patients who had
known signiﬁcant bleeding risk.
Methods
Study design. This retrospective study used prospectively
collected data from patients enrolled in the RIETE(Computerized Registry of Patients With Venous Thrombo-
embolism) (Online Appendix) (7,8). All patients provided
written or oral informed consent for participation in the registry
in accordance with local ethics committee requirements.
Study cohort and deﬁnition of treatment groups. At each
participating site, RIETE investigators aimed to enroll con-
secutive patients who had acute symptomatic or asymptom-
atic VTE conﬁrmed by using objective testing that consisted
of: high-probability ventilation/perfusion scintigraphy (9);
positive contrast-enhanced PE protocol; helical chest com-
puted tomography (CT) (single or multidetector CT) for PE
(10); or lower limb venous compression ultrasonography pos-
itive for proximal DVT (11). This study excluded those who
had asymptomatic VTE. Of the patients treated with an IVC
ﬁlter, this study only included those patients who had an IVC
ﬁlter inserted during the ﬁrst 30 days after VTE diagnosis
because of known signiﬁcant bleeding risk (i.e., absolute or
relative contraindication to anticoagulation therapy) as deter-
mined by the local investigator (i.e., not independently
adjudicated).
Treated patients were deﬁned as those who received an
IVC ﬁlter (with or without concomitant anticoagulation)
because of known signiﬁcant bleeding risk. Control patients
were deﬁned as those with distributions of observed base-
lines covariates (i.e., similar baseline risk of bleeding) com-
parable to treated patients (see the Statistical analysis
section) who did not receive a ﬁlter but underwent antico-
agulant therapy.
Baseline variables. Patients enrolled in the RIETE regis-
try had data collected from around the time of VTE diag-
nosis that included but was not limited to: age; sex; weight;
presence of coexisting conditions such as chronic heart or
lung disease; recent (<30 days before VTE) major bleeding;
presence of risk factors for PE, including active cancer
(deﬁned as newly-diagnosed cancer or cancer being treated
[i.e., surgery, chemotherapy, radiotherapy, hormonal or
support therapy]); recent immobility (deﬁned as nonsurgical
patients assigned to bed rest with bathroom privileges
for 4 days in the 2 months before VTE diagnosis); surgery
(deﬁned as those who had undergone major surgery in the
2 months before VTE); clinical signs and symptoms on
admission, including heart rate and systolic blood pressure;
and laboratory results at hospital admission that included
hemoglobin (Hb), platelet count, and serum creatinine.
Study outcomes. This study used all-cause mortality
through 30 days after initiation of anticoagulant treatment or
ﬁlter insertion as the primary endpoint, and 30-day PE-
related mortality, recurrent VTE, and major bleeding as
secondary endpoints. The RIETE investigators assessed
mortality presence, cause, and date by using medical record
review and proxy interviews when necessary. Clinicians at
RIETE-enrolling sites managed patients with suspected
recurrences according to their local practice. Typically, the
RIETE investigators deﬁned recurrent DVT as a new
noncompressible vein segment or an increase of the vein
diameter by at least 4 mm compared with the last available
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1677measurement on venous ultrasonography (12); recurrent PE
as a new ventilation/perfusion mismatch on lung scan or a
new intraluminal ﬁlling defect on spiral CT of the chest
(10); and major bleeding episodes as those that required a
transfusion of at least 2 U of blood, were retroperitoneal,
spinal, or intracranial, or were fatal (13).
Treatment and follow-up. Clinicians at RIETE-enrolling
sites managed patients according to their local practice (i.e.,
there was no standardization of treatment). In the RIETE
registry, most patients received initial anticoagulation with
intravenous UFH or subcutaneous LMWH or fondapar-
inux, and overlap and long-term therapy with an oral
vitamin K antagonist. Clinicians administered thrombolytic
treatment and/or inotropic support as deemed appropriate.
In general, clinicians used thrombolytic treatment of acute
PE in patients with cardiogenic shock (e.g., persistent
systolic arterial pressure<90mmHg in the setting of clinical
signs of organ hypoperfusion [clouded sensorium, oliguria,
cold and clammy skin, or lactic acidosis]). The RIETE
registry recorded information related to patient outcomes
through 3 months after the diagnosis of acute VTE, and
this study analyzed outcomes through 30 days after initiation
of VTE treatment (i.e., anticoagulation or ﬁlter insertion).
Statistical analysis. Chi-square or Fisher exact tests were
used to compare categorical data between groups. The
Kolmogorov-Smirnov test was used to assess continuous
data for a normal distribution. We used 2-tailed unpaired
Student t tests to compare normally distributed continuous
data between 2 groups, and the Mann-Whitney U test
was used for non-normally distributed continuous dataFigure 1 Patient Flow Diagram
DVT ¼ deep vein thrombosis; IVC ¼ inferior vena cava; PE ¼ pulmonary embolism; VTE ¼comparisons. Multivariate adjustments were made for age,
cancer, recent or active bleeding, immobilization, heart rate,
systolic blood pressure, creatinine levels, platelet count, and
Hb levels via logistic regression to see if insertion of a ﬁlter was
an independent signiﬁcant predictor of all-cause mortality in
the entire sample (N ¼ 40,142).
Because clinicians did not randomly allocate ﬁlter ther-
apy, the patients who received an IVC ﬁlter likely sys-
tematically differed from patients who did not receive one
with respect to baseline characteristics, clinical course,
clinical examination and test ﬁndings, and comorbid con-
ditions. A propensity score adjustment was used to com-
pare treatment effects for patients with similar predicted
probabilities of receiving a ﬁlter (14). Logistic regression
was used to estimate propensity scores, and we modeled
the log odds of the probability that a patient received a
ﬁlter by using baseline demographic and clinical variables
(see the Baseline variables section for deﬁnitions) that were
previously shown to be associated with mortality or treat-
ment selection. These variables included: patient age at
time of diagnosis of VTE; presence or absence of recent
(<30 days before VTE) major bleeding; presence or
absence of active bleeding at the time of diagnosis of VTE;
presence or absence of risk factors for VTE that included
active cancer or recent immobility; clinical signs and
symptoms on admission, including heart rate and systolic
blood pressure; and anemia (deﬁned as Hb level <13 g/dl
in men and <12 g/dl in women) (15), thrombocytopenia
(platelet count <100  109/l), and abnormal serum
creatinine levels (>2 mg/dl).venous thromboembolism.
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1678After generation of the propensity scores, we sought to
estimate the reduction in 30-day overall mortality attribut-
able to the insertion of a ﬁlter by using a greedy matched-
paired analysis that has a 1:1 matching algorithm and does
not allow for replacements. We randomly selected a patient
in the treatment group and then matched that patient with
the nearest patient in the control group within a ﬁxed caliper
width of 0.05 (16). To assess the success of the matching
procedure, we measured standardized differences (measured
in percentage points) in observed confounders between the
matched groups (17). The ﬁlter effect was estimated by
using generalized estimating equation methods to incorpo-
rate the matched-pairs design, and we adjusted for those
covariates that remained unbalanced after matching (18).
The data were analyzed according to 3 different propensity
score models: 1 for any VTE, 1 for symptomatic DVT
(without symptomatic PE), and 1 for symptomatic PE. The
area under the curve (AUC) was calculated for each receiver-
operating characteristic curve to quantify propensity score
model accuracy and its ability to correctly discriminate or
identify those patients who received and those who did not
receive an IVC ﬁlter.
Several sensitivity analyses were performed. First, we
examined the effect of ﬁlters inserted during the ﬁrst 7 days
after the diagnosis of VTE. Because most fatal PEs occur
within the ﬁrst few days after VTE diagnosis (8), we ex-
pected that the effectiveness of ﬁlters would be greatest soonTable 1
Clinical Characteristics of Patients With
Who Did or Did Not Receive an IVC Filte
R
Clinical characteristics
Age, yrs
Age >80 yrs
Male
Weight, kg
Risk factors for VTE
History of VTE
Cancer
Recent surgery
Immobilization for 4 days
Comorbid diseases
Chronic lung disease (n ¼ 4,894)
Chronic heart disease (n ¼ 4,360)
Recent major bleeding
Antiplatelet therapy (n ¼ 18,685)
NSAIDs (n ¼ 18,670)
Clinical symptoms and signs at presentation
Heart rate 110 beats/min
Arterial oxyhemoglobin saturation <90% (n ¼ 3,036)
SBP <100 mm Hg
Laboratory ﬁndings
Abnormal creatinine levels (>2 mg/dl)
Thrombocytopenia (<100  109/l)
Hemoglobin, g/dl
Values are mean  SD, n (%), or n/N (%).
IVC ¼ inferior vena cava; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugsafter the VTE diagnosis. Second, we evaluated various
caliper widths iteratively until between-group standardized
differences were minimized. Finally, we repeated all analyses
for the secondary endpoints.
We used psmatch2 for the propensity score analyses
and Stata version 11.2 for Windows (StataCorp, College
Station, Texas) for all other analyses.
Results
A total of 40,975 patients were identiﬁed with objectively-
conﬁrmed VTE enrolled in the RIETE registry during the
study period. After the exclusion of 230 (0.6%) patients with
asymptomatic VTE and 603 (1.5%) patients who received a
ﬁlter for reasons other than a relative or absolute contrain-
dication to anticoagulation, the study cohort consisted of
40,142 patients with conﬁrmed DVT (51%), PE (32%), or
both (17%) (Fig. 1).
Unmatched cohort. Of the 371 patients who received an
IVC ﬁlter, 152 (41%) had DVT (without symptomatic PE)
and 219 had PE (with or without symptomatic DVT).
Patients treated with ﬁlters and those treated without ﬁlters
differed signiﬁcantly in pre-existing medical conditions and
relevant clinical, physiological, and laboratory parameters
(Tables 1 and 2). Patients who received a ﬁlter had more
comorbid diseases (cancer, recent surgery, immobility,
congestive heart failure, chronic lung disease, and recentDeep Vein Thrombosis
r
eceived Filter
(n ¼ 152)
Did Not Receive Filter
(n ¼ 20,351) p Value
69.3  14.8 63.7  17.9 <0.001
38 (25.0) 4,009 (19.7) 0.12
86 (56.6) 10,589 (52.0) 0.30
71.3  15.8 74.3  15.0 0.01
11 (7.2) 3,318 (16.3) <0.01
60 (39.5) 4,283 (21.0) <0.001
40 (26.3) 2,162 (10.6) <0.001
87 (57.2) 4,969 (24.4) <0.001
10 (15.6) 1,678 (34.7) <0.01
10 (15.9) 838 (19.5) 0.57
72 (47.4) 360 (1.8) <0.001
17 (12.7) 2,080 (11.2) 0.69
7 (5.2) 1,015 (5.5) 0.90
13 (8.6) 848 (4.2) 0.01
3/30 (10) 229/3,006 (7.6) 0.89
7 (4.6) 541 (2.6) 0.22
39 (25.6) 2,565 (12.6) <0.001
14 (9.2) 511 (2.5) <0.001
11.1  2.4 12.9  2.1 <0.001
; SBP ¼ systolic blood pressure; VTE ¼ venous thromboembolism.
Table 2
Clinical Characteristics of Patients With Pulmonary Embolism
Who Did or Did Not Receive an IVC Filter
Received Filter
(n ¼ 219)
Did Not Receive Filter
(n ¼ 19,420) p Value
Clinical characteristics
Age, yrs 68.5  14.3 67.9  16.7 0.60
Age >80 yrs 50 (22.8) 5,134 (26.4) 0.26
Male 108 (49.3) 8,936 (46.0) 0.27
Weight, kg 73.2  15.2 74.7  15.3 0.15
Risk factors for VTE
History of VTE 23 (10.5) 2,866 (14.7) 0.09
Cancer 81 (37.0) 4,151 (21.4) <0.001
Recent surgery 34 (15.5) 2,352 (12.1) 0.15
Immobilization for 4 days 85 (38.8) 4,676 (24.1) <0.001
Comorbid diseases
Chronic lung disease (n ¼ 6,557) 20 (30.8) 2,662 (41.0) 0.12
Chronic heart disease (n ¼ 5,989) 11 (17.7) 1,700 (28.7) 0.08
Recent major bleeding 70 (32.0) 362 (1.9) <0.001
Antiplatelet therapy (n ¼ 18,656) 32 (15.4) 2,928 (15.9) 0.95
NSAIDs (n ¼ 18,638) 7 (3.4) 945 (5.1) 0.33
Clinical symptoms and signs at presentation
Syncope 48 (21.9) 2,919 (15.0) <0.01
Chest pain 102 (46.6) 9,211 (47.4) 0.85
Dyspnea 170 (77.6) 15,706 (80.9) 0.26
Heart rate 110 beats/min 48 (21.9) 4,022 (20.7) 0.72
Arterial oxyhemoglobin saturation <90% (n ¼ 13,977) 55 (37.2) 4,140 (29.9) 0.07
SBP <100 mm Hg 30 (13.7) 1,488 (7.7) <0.01
Laboratory ﬁndings
Abnormal creatinine levels (>2 mg/dl) 39 (17.8) 3,442 (17.7) 0.97
Thrombocytopenia (<100  109/l) 15 (6.8) 409 (2.1) <0.001
Hemoglobin, g/dl 12.0  2.2 13.0  2.0 <0.001
Values are mean  SD or n (%).
Abbreviations as in Table 1.
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1679bleeding), signs of clinical severity (tachycardia and hypo-
tension), and laboratory abnormalities (renal failure, anemia,
and thrombocytopenia) compared with those who did not
receive a ﬁlter.Table 3 Characteristics of VTE Patients at Cohort Entry, Before and
Before Matching
No Filter
(n ¼ 39,771)
Filter
(n ¼ 371)
Demographic
Age, yrs 65.7  17.5 68.9  14.5
Comorbidities
Cancer 21.2 38.0
Immobilization 24.3 46.4
Recent or active bleeding 1.6 35.3
Physical examination
Heart rate, beats/min 87  19 91  19
SBP, mm Hg 131  23 127  24
Laboratory measures
Abnormal creatinine levels (>2 mg/dl) 15.1 21.0
Thrombocytopenia (<100 x 109/l) 2.3 7.8
Anemia* 19.1 44.7
Values are mean  SD or %. *Deﬁned as hemoglobin <13 g/dl in men and <12 g/dl in women.
Abbreviations as in Table 1.Overall, 1,823 (4.5%) of 40,142 patients died (all-cause
mortality) through 30 days after the diagnosis of VTE.
Three percent of the patients with DVT (602 of 20,503
patients) died during the 1-month follow-up period,After Matching
After Matching
Standardized
Difference
(%)
No Filter
(n ¼ 344)
Filter
(n ¼ 344)
Standardized
Difference
(%)
19.5 69.8  15.3 69.1  14.2 4.8
37.4 34.6 36.6 4.2
47.5 45.3 45.6 0.6
96.5 33.7 33.4 0.6
21.5 91  20 95  19 1.0
16.8 128  24 127  25 1.4
15.4 21.2 20.6 1.5
25.3 4.9 6.7 7.7
57.1 46.8 43.9 5.8
Table 4 Patient Characteristics According to Initial Presentation, Before and After Matching
Deep Vein Thrombosis
Before Matching After Matching
No Filter
(n ¼ 20,351)
Filter
(n ¼ 152)
Standardized
Difference
(%)
No Filter
(n ¼ 134)
Filter
(n ¼ 134)
Standardized
Difference
(%)
Demographic
Age, yrs 63.7  17.9 69.3  14.8 34.2 71.9  14.8 69.7  14.3 15.7
Comorbidities
Cancer 21.0 39.5 41.1 29.9 36.6 14.3
Immobilization 24.4 57.2 70.8 60.4 56.7 7.5
Recent or active bleeding 1.5 44.7 119.4 41.0 41.8 1.6
Physical examination
Heart rate, beats/min 81  15 85  17 23.4 88  17 85  17 19.3
SBP, mm Hg 133  21 130  22 12.4 128  21 130  22 7.3
Laboratory measures
Abnormal creatinine levels (>2 mg/dl) 12.6 25.7 33.8 31.3 26.1 11.5
Thrombocytopenia (<100  109/l) 2.5 9.2 28.8 4.5 8.2 15.2
Anemia* 20.2 56.6 80.7 54.5 56.0 3.0
Pulmonary Embolism
No Filter
(n ¼ 19,420)
Filter
(n ¼ 219)
No Filter
(n ¼ 210)
Filter
(n ¼ 210)
Demographic
Age, yrs 67.9  16.7 68.5  14.3 4.3 69.2  14.8 68.8  14.2 2.7
Comorbidities
Cancer 21.0 37.0 35.8 36.2 36.7 1.0
Immobilization 24.1 38.8 81.4 40.0 38.6 2.9
Recent or active bleeding 1.7 28.8 32.1 28.8 28.8 0
Physical examination
Heart rate, beats/min 93  20 95  19 10.8 97  21 95  19 8.0
SBP, mm Hg 130  25 125  26 16.9 125  27 126  26 8.0
Laboratory measures, %
Abnormal creatinine levels (>2 mg/dl) 17.7 17.8 0.3 15.7 17.1 3.8
Thrombocytopenia (<100  109/l) 2.1 6.8 22.9 4.8 5.7 4.0
Anemia* 18.0 36.5 42.5 36.2 36.2 0
Values are mean  SD or %. *Deﬁned as hemoglobin <13 g/dl in men and <12 g/dl in women.
SBP ¼ systolic blood pressure.
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1680compared with 6.2% of the patients with PE (1,221 of
19,639 patients). Of the patients who received an IVC ﬁlter,
7.3% (27 of 371 patients) died during the 30-day follow-up
period. Of those who did not receive a ﬁlter, 4.5% (1,796 of
39,771 patients) died (absolute difference [AD]: 2.8% [95%
conﬁdence interval (CI) of the AD: 0.5% to 5.9%]; p ¼
0.02) during follow-up. Of the DVT patients (without
symptomatic PE) who received an IVC ﬁlter, 5.9% died
during the follow-up period, compared with 2.9% of those
who did not receive a ﬁlter (AD: 3.0% [95% CI of the AD:
0.2% to 8.0%]; p ¼ 0.05) during follow-up. Of the PE
patients, with or without DVT, who received an IVC ﬁlter,
8.2% died, whereas 6% of those who did not receive a ﬁlter
died (AD: 2.0% [95% CI of the AD: 0% to 6.4%]; p ¼ 0.28)
during follow-up.
Matched cohort. The matching of patients presenting with
any acute VTE yielded 344 patients treated with ﬁlters and
344 patients treated without ﬁlters. This model showed good
to excellent discrimination, with an AUC of 0.80. The
standardized differences of <10% for all matched variables
supported the assumption of balance between treatment
groups in observed confounders (Table 3). We successfullymatched 134 patients with acute symptomatic DVT who
received a ﬁlter with 134 patients who did not on the basis of
propensity score (AUC: 0.87). The matching process elimi-
nated some signiﬁcant differences that existed between groups
regarding pre-existing medical conditions or relevant clinical,
physiological, and laboratory parameters (Table 4). Propensity
analyses of the subgroup of patients with PE used 210matched
pairs (210 patients from each group) (AUC: 0.74). The
matched sample showed good balance for each variable.
Among those patients with DVT who did not have a
ﬁlter, 128 received anticoagulant therapy and 6 did not. Of
the 128 anticoagulated patients with DVT, 121 patients
(95%) received therapy with LMWH, 4 (3%) received UFH,
and 3 (2%) received fondaparinux. Among those patients
with DVT who had a ﬁlter inserted, 80 received anticoag-
ulants and 54 were not anticoagulated. A total of 67 patients
(84%) received therapy with LMWH, 12 (15%) received
UFH, and 1 (1%) received fondaparinux. Figure 2 shows
LMWH dosing regimens among matched patients who
were treated with or without ﬁlters.
Among those patients with PE who did not have a ﬁlter,
200 received anticoagulant therapy and 10 were not
Figure 2 LMWH Dosing Regimens
Low-molecular-weight heparin (LMWH) dosing regimens among matched patients
with (A) DVT or (B) PE who were treated with or without an inferior vena cava ﬁlter.
Abbreviations as in Figure 1.
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1681anticoagulated. Of the 200 anticoagulated patients with PE,
174 patients (87%) received therapy with LMWH, 23 (12%)
received UFH, and 3 (1%) received fondaparinux. Among
those patients with PE who had a ﬁlter inserted, 118
received anticoagulants and 92 were not anticoagulated. A
total of 84 patients (71%) received therapy with LMWH,
31 (26%) received UFH, and 3 (3%) received fondaparinux.
Figure 2 shows the LMWH dosing regimens among
matched patients who were treated with or without ﬁlters.
Filter insertion was associated with a nonstatistically sig-
niﬁcant lower mortality rate than nonﬁlter treatment in the
matched cohort of patients with any VTE (6.6% vs. 10.2%;
risk difference: –3.6% [95% CI: –7.7% to 0.7%]; p ¼ 0.12).
A similar reduction in 30-day all-cause mortality was evident
for both subtypes of VTE (DVT and PE) (Table 5).
Analysis of propensity score–matched pairs (n ¼ 344 pairs)
showed a statistically signiﬁcant decreased risk of PE-related
mortality for ﬁlter insertion compared with no insertion
(1.7% vs. 4.9%; risk difference: –3.2% [95% CI: –6.2% to
–0.5%]; p ¼ 0.03).
After propensity score matching, there was no signiﬁcant
difference in the rate of major bleeding at 30 days betweenpatients receiving ﬁlters and those not receiving ﬁlters (3.8%
vs. 5.2%; risk difference: –1.4% [95% CI: –1.7% to 4.5%];
p ¼ 0.35) (Table 5). This difference was also nonstatistically
signiﬁcant in the matched cohort of patients who initially
manifested PE (3.8% vs. 6.7%; risk difference: –2.9% [95%
CI: –1.4% to 7.2%]; p ¼ 0.18). In the subgroup of patients
with DVT, the number of events did not allow for
comparisons.
The rates of recurrent VTE at 30 days in the matched
cohort of patients with any VTE were signiﬁcantly higher
among patients receiving ﬁlters than among those not
receiving ﬁlters (6.1% vs. 0.6%; risk difference: 5.5% [95%
CI: 2.8% to 8.2%]; p < 0.001). Of the 21 recurrent events
that occurred in patients who received a ﬁlter, 15 (71%) were
DVT and 6 (29%) were PEs. Two patients who did not
receive a ﬁlter experienced a PE recurrence during follow-
up. In the matched cohort of patients with PE, the recur-
rent VTE rate was signiﬁcantly higher in those patients who
received an IVC ﬁlter versus those who did not (8.1% vs.
1.0%; risk difference: 7.1% [95% CI: 3.2% to 11.0%]; p <
0.001). In the subgroup of matched patients with DVT, the
number of events did not allow for comparisons.
Sensitivity analyses. When we evaluated ﬁlters inserted
during the ﬁrst 7 days after the diagnosis of VTE, results
mimicked the ﬁndings of the primary analysis: mortality
rates in the group receiving ﬁlters tended to be lower than
those in the group not receiving ﬁlters, whereas VTE re-
currences were signiﬁcantly higher. Similarly, we found
consistent results when we evaluated various caliper widths
(0.1 and 0.2 SD).
Discussion
Uncertainty surrounding the efﬁcacy of IVC ﬁlters exists. The
results of our study show that, in patients with signiﬁcant
bleeding risk,ﬁlter insertionwas associatedwith a lower risk of
30-day PE-related mortality compared with anticoagulant
therapy, whereas it was associated with a higher risk of
recurrent VTE. IVC ﬁlter therapy had a similar effect on each
of the study endpoints in the subgroups of patients who pre-
sented solely with DVT or with PE (with or without DVT).
However, study design limitations do not imply a causal
relationship between ﬁlter insertion and outcome.
Despite the relatively frequent use of IVC ﬁlters, few
prospective, randomized controlled trials have assessed their
efﬁcacy and safety in patients with acute symptomatic VTE
(19). Decousus et al. (%) evaluated the efﬁcacy of permanent
vena cava ﬁlters in the PREPIC study, in which 400 patients
with proximal DVT were randomly selected to receive a
permanent vena cava ﬁlter (6). The study also randomized
patients to receive 1 of 2 classes of anticoagulants. The study
did not detect a difference in the death rate at any time
during follow-up when comparing those with and without
vena ﬁlters. Permanent ﬁlters reduced the risk of PE but
increased the risk of DVT (5). Although this study provided
helpful information, it did not address the value of IVC
Table 5 Adjusted Clinical Outcomes
30-Day Outcome Filter No Filter OR (95% CI) p Value
Any VTE
Death 23/344 (6.6) 35/344 (10.2) 0.63 (0.36–1.12) 0.12
PE-related death 6/344 (1.7) 17/344 (4.9) 0.35 (0.15–0.43) 0.03
Major bleeding 13/344 (3.8) 18/344 (5.2) 0.71 (0.35–1.46) 0.35
Recurrent VTE 21/344 (6.1) 2/344 (0.6) 11.12 (2.56–48.19) <0.001
Any DVT*
Death 8/134 (6.0) 15/134 (11.2) 0.53 (0.20–1.44) 0.21
Major bleeding 5/134 (3.7) 5/134 (3.7) NCy
Recurrent VTE 4/134 (3.0) 2/134 (1.5) NCy
Any PE
Death 15/210 (7.1) 24/210 (11.4) 0.60 (0.19–1.21) 0.15
Major bleeding 8/210 (3.8) 14/210 (6.7) 0.55 (0.23–1.32) 0.18
Recurrent VTE 17/210 (8.1) 2/210 (1.0) 9.16 (2.24–32.48) <0.001
Values are n/N (%). *Adjusted for variables not achieving 10% SD after matching. Final model included the following covariates: age, cancer, heart
rate, creatinine levels, and thrombocytopenia. yNot calculated (NC) because the number of events precluded adjustment.
CI ¼ conﬁdence interval; DVT ¼ deep vein thrombosis; OR ¼ odds ratio; PE ¼ pulmonary embolism; other abbreviations as in Table 1.
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1682ﬁlters versus anticoagulant therapy in those situations in
which ﬁlters are commonly advocated (i.e., absolute
contraindication to anticoagulation).
Many studies have demonstrated the relative efﬁcacy and
safety of standard anticoagulant therapy in hemodynami-
cally-stable patients with PE. For patients with VTE and
known signiﬁcant bleeding risk, this study suggested that
use of an IVC ﬁlter, compared with anticoagulant treatment,
was associated with fewer deaths attributable to PE. Patients
treated with an IVC ﬁlter did not receive anticoagulation
therapy or received lower doses of anticoagulants than those
not treated with a ﬁlter. Thus, ﬁlter insertion may have
prevented some fatal PE recurrences. However, the IVC
ﬁlter group had a higher rate of recurrent symptomatic VTE
compared with the nonﬁlter group. Lack of anticoagulant
treatment or thrombosis at the ﬁlter site may have caused the
higher recurrent DVT rate. Contrary to what might have
been expected, IVC ﬁlters increased the rate of symptomatic
PE recurrence. Because patients treated with an IVC ﬁlter
had a lower PE-related mortality than those not treated
with a ﬁlter, we speculate that ﬁlters did not allow large PE
to recur.
The risk of bleeding and other variables in an individual
patient should lead to tailoring of the intensity and type of
treatment of symptomatic VTE (20). In this study, clinicians
withheld or used lower doses of anticoagulants in patients
treated with an IVC ﬁlter, and this approach had a non-
statistically signiﬁcant lower 30-day major bleeding rate
compared with standard anticoagulation. These ﬁndings
occurred even though the ﬁlter-treated subgroup had more
risk factors for bleeding than the anticoagulated cohort.
Predicting which patients will have major bleeding during
anticoagulant therapy after VTE remains difﬁcult. Re-
searchers have developed decision tools to better deﬁne the
risk of anticoagulant-associated bleeding (21–23). To
determine whether such models can help clinicians decidewhich treatment options to choose will require further
prospective studies in various at-risk groups.
Using data from the Nationwide Inpatient Sample, Stein
et al. (4) reported decreased case fatality rates with vena cava
ﬁlters in patients in unstable condition, regardless of whether
they received thrombolytic therapy, and in stable patients
who received thrombolytic therapy. However, to the best of
our knowledge, no other population-based study has reported
on the effectiveness of IVC ﬁlter use as an acute management
strategy for patients with acute VTE and known signiﬁcant
bleeding risk. According to a scientiﬁc statement from the
American Heart Association (24), adult patients with any
conﬁrmed acute PE (or proximal DVT) with contraindica-
tions to anticoagulation or with active bleeding complications
should receive an IVC ﬁlter. Results of the present investi-
gation support this recommendation. An ongoing multi-
center randomized trial (PREPIC II [Prevention of
Recurrent Pulmonary Embolism by Vena Cava Interruption
[PREPIC2]]; NCT00457158) aims to determine the efﬁ-
cacy and safety of insertion of an IVC ﬁlter in the prevention
of PE recurrence (25).
Study limitations. Selection bias could have skewed the
study sample. However, the broad range of patients with acute
symptomatic VTE from multiple medical centers, countries,
and treatment settings enrolled in the RIETE registry
decreased the likelihood of the inclusion of a skewed popu-
lation in this study. The population-based sample we used
described the effects of ﬁlters in “real-world” clinical care and
enhanced the generalizability of the ﬁndings. Confounding
may have affected the results of this observational study. We
used propensity score matching to make the patient groups
comparable according to the measured confounders (i.e.,
baseline risk of bleeding), and we successfully eliminated the
observed differences. However, residual confounding may
still have occurred. The similar results from many of the
sensitivity and secondary analyses provided evidence of the
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soundness of the conclusions. Despite the large number of
patients assessed for this study from the RIETE registry,
the relatively small sample size of the propensity-matched
cohorts lowered the statistical power of the study and there-
fore increased the chance that the study would not detect
a statistically signiﬁcant difference in outcomes between the
treatment groups (i.e., type II error). Finally, concomitant
anticoagulation might have accounted for some of the differ-
ences between the groups’ outcomes. However, because clini-
cians typically use lower doses of anticoagulants in patients
with a high risk of bleeding, the study ﬁndings suggest that
thedesignmight have caused a slight bias againstﬁlter insertion.
Conclusions
In patients with acute symptomatic VTE and known sig-
niﬁcant bleeding risk, IVC ﬁlter therapy may reduce the risk
of PE-related mortality compared with anticoagulant ther-
apy. However, lack of anticoagulation or thrombosis asso-
ciated with IVC ﬁlters could increase the risk of recurrent
VTE. Randomized controlled trials of retrievable ﬁlters
might help to identify subgroups of patients at high risk of
death who might have a favorable risk to beneﬁt ratio for
treatment with ﬁlter insertion.
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APPENDIX
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